FIBROGEN, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.04 USD | +1.96% |
|
-9.57% | +17.34% |
| Sales 2024 * | 155M 12.44B | Sales 2025 * | 169M 13.55B | Capitalization | 103M 8.28B |
|---|---|---|---|---|---|
| Net income 2024 * | -142M -11.37B | Net income 2025 * | -102M -8.17B | EV / Sales 2024 * | 0.67 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.61 x |
| P/E ratio 2024 * |
-0.73
x | P/E ratio 2025 * |
-1.04
x | Employees | 486 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.08% |
More Fundamentals
* Assessed data
More news
Latest transcript on FibroGen, Inc.
More recommendations
More press releases
More news
| 1 day | +1.96% | ||
| 1 week | -9.57% | ||
| Current month | -55.74% | ||
| 1 month | -57.38% | ||
| 3 months | +11.12% | ||
| 6 months | +94.39% | ||
| Current year | +17.34% |
1 week
0.90
1.26
1 month
0.902.59
Current year
0.692.93
1 year
0.3319.47
3 years
0.3330.12
5 years
0.3357.21
10 years
0.3368.55
| Managers | Title | Age | Since |
|---|---|---|---|
Thane Wettig
CEO | Chief Executive Officer | 59 | 21/06/20 |
Juan Graham
DFI | Director of Finance/CFO | 48 | 06/09/21 |
James Schoeneck
CHM | Chairman | 66 | 31/03/10 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jeffrey Edwards
BRD | Director/Board Member | 64 | 27/10/15 |
| Director/Board Member | 59 | 05/08/15 | |
May Kin Ho
BRD | Director/Board Member | 71 | 05/12/18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.83% | 1 M€ | -5.79% | - | |
| 0.13% | 0 M€ | 0.00% | - | |
| 0.12% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 1.04 | +1.96% | 653,815 |
| 25/04/24 | 1.02 | +3.63% | 1,259,232 |
| 24/04/24 | 0.9843 | -8.01% | 2,170,507 |
| 23/04/24 | 1.07 | -6.14% | 1,349,229 |
| 22/04/24 | 1.14 | -0.87% | 803,876 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in Phase III clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and in Phase 2/3 for the treatment of metastatic pancreatic cancer and Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. It also develops FG-3165: Anti-Gal9 Antibody and FG-3175: Anti-CCR8 Antibody.
Calendar
05/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
3
Last Close Price
1.04
USD
Average target price
1.75
USD
Spread / Average Target
+68.27%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +17.34% | 103M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- FGEN Stock
